Efectividad y seguridad de daclatasvir/ sofosbuvir con o sin ribavirina en pacientes infectados por el genotipo 3 del virus de la hepatitis C: resultados en práctica clínica real by Margusino-Framiñán, Luis et al.
Rev Esp Quimioter 2019;32(2): 137-144 137
©The Author 2019. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 
International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
Efectividad y seguridad de daclatasvir/
sofosbuvir con o sin ribavirina en pacientes 
infectados por el genotipo 3 del virus de la 
hepatitis C. Resultados en práctica clínica real
Objetivos. Los antivirales de acción directa han demostra-
do una alta eficacia en todos los genotipos del virus de la he-
patitis C (VHC), pero los tratamientos para el genotipo 3 (G3) 
siguen siendo un desafío, principalmente en pacientes cirróticos. 
El objetivo de este estudio es analizar la efectividad y la seguri-
dad del daclatasvir asociado con sofosbuvir con o sin ribavirina 
en pacientes infectados por G3-VHC en la práctica clínica real.
Pacientes y métodos. Estudio observacional, prospectivo, 
de cohorte de más de 2,5 años, en pacientes adultos infecta-
dos con G3-VHC, en todos los estadios de fibrosis, incluidos los 
pacientes con cirrosis descompensada. El tratamiento fue una 
combinación de sofosbuvir 400 mg / día + daclatasvir 60 mg / 
día, con o sin una dosis de ribavirina ajustada por peso durante 
12 o 24 semanas. El criterio de valoración principal de eficacia 
fue la tasa de respuesta virológica sostenida 12 semanas des-
pués del tratamiento (RVS12). La variable principal de seguri-
dad fue la tasa de suspensiones de tratamiento secundaria a 
eventos adversos graves.
Resultados. Se incluyeron 111 pacientes, 32.4% cirróti-
cos y 29.9% con experiencia previa de tratamiento antiviral. 
La tasa global de RVS12 fue del 94,6%, mientras que la tasa de 
RVS12 en pacientes con estadio de fibrosis F3-4 fue del 90,8% 
frente al 100% en pacientes con fibrosis F0-2 (p = 0,03). En 
pacientes cirróticos, la RVS12 fue del 100% en comparación 
con el 40%, dependiendo de si se agregó o no ribavirina a da-
clatasvir / sofosbuvir (p = 0,001). Ninguna otra variable basal 
del paciente o del tratamiento influyó en la efectividad del tra-
tamiento. No se observó ninguna suspensión del tratamiento 
secundario a eventos adversos graves.
Conclusiones. Daclatasvir / sofosbuvir ± ribavirina es 
altamente efectivo en pacientes infectados por G3-VHC. Los 
ABSCTRACT
Objectives. Direct-acting antivirals have shown high ef-
ficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 
(G3) treatments continue to be a challenge, mainly in cirrhotic 
patients. The aim of this study is to analyse effectiveness and 
safety of daclatasvir associated with sofosbuvir with or without 
ribavirin in G3-HCV infected patients in real clinical practice.
Patients and methods. An observational, prospective, 
cohort study over 2.5 years, in G3-HCV infected adult patients, 
in all fibrosis stages including patients with decompensated 
cirrhosis. Treatment was a combination of sofosbuvir 400 mg/
day + daclatasvir 60 mg/day, with or without a weight-adjust-
ed dosing of ribavirin for 12 or 24 weeks. The primary efficacy 
endpoint was sustained virologic response rates 12 weeks after 
therapy (SVR12). The primary safety endpoint was treatment 
withdrawal rates secondary to severe adverse events. 
Results. A total of 111 patients were enrolled, 32.4% cir-
rhotics and 29.9% treatment-experienced. The global SVR12 rate 
was 94.6%, while the SVR12 rate in F3-4 fibrosis stage patients 
was 90.8% versus 100% in patients with F0-2 fibrosis (p=0.03). 
In cirrhotic patients, SVR12 was 100% versus 40% depending 
on whether ribavirin was added or not to daclatasvir/sofosbuvir 
(p=0.001). No other patient or treatment basal variables influ-
enced the treatment effectiveness. No patient treatment with-
drawal secondary to severe adverse events was observed.
Conclusions. Daclatasvir/sofosbuvir ± ribavirin is highly 
effective in G3-HCV infected patients. Advanced degrees of 
fibrosis significantly decrease the effectiveness of this treat-
ment, which motivates the need for the addition of ribavirin 
in cirrhotic patients. The regimen was safe and well tolerated.
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Based on the above, the objective of this study is to an-
alyse the effectiveness and safety of 12-24 weeks treatment 
regimens of DCV associated with SOF with or without RBV in 
a cohort of G3-HCV infected patients in real clinical practice.
PATIENTS AND METHODS
Study design and patient selection. We are looking at 
a unicentric, observational, prospective, cohort study of G3-
HCV infected patients who started antiviral treatment with 
DCV/SOF±RBV between January 2015 and June 2017 and who 
had reached week 12 post-treatment before January 2018. 
Treatment decisions corresponded to the prescribing special-
ist (infectious diseases specialists or hepatologist), under usual 
clinical practice conditions valid during the study period. The 
therapeutic regimen was the one authorised by the European 
Medicine Agency (EMA) and consisted of a fixed combination 
of SOF 400 mg/day (Sovaldi®; Gilead Sciences Internation-
al Ltd.) plus DCV 60 mg/day (Daklinza®; Bristol Myers Squibb 
Pharma EEIG), associated or not with the corresponding dose 
of RBV (Ribavirina Normon®; Normon Lab.), adjusted to body 
weight and patient characteristics. It was administered for 12 
or 24 weeks, based on EMA recommendations. Inclusion cri-
teria selected adult patients (≥18 years of age), with G3-HCV 
chronic infection, naïve or treatment-experienced to peg-INF 
+ RBV or DAAs, in all fibrosis stages (F0-4) including patients 
with decompensated cirrhosis or portal hypertension, human 
immunodeficiency virus (HIV) co-infected patients or liver 
transplant patients.
Effectiveness and safety variables. Pharmacological 
treatment effectiveness and a safety evaluation were carried 
out through SiMON [19], a local intelligent computerised mon-
itoring system designed specifically for CHC patients on anti-
viral treatment. This system recorded, through an automated 
and anonymous way from clinical history data, the necessary 
effectiveness events for the evaluation of antiviral treatment 
based on algorithms previously defined by physicians and 
pharmacists responsible for CHC patients. These systems also 
allowing for registering patient reported outcomes as the ad-
verse events (AEs). 
The HCV viral load was determined using the real-time 
PCR technique with the Cobas® AmpliPrep platform from Ro-
che; the kit is HCV Quantitative Test, version 2.0. The limits of 
detection and quantification in plasma (there is no significant 
difference in the serum) were 11 IU/mL (10-13 IU/mL, 95%CI) 
for the lower limit of detection (LOD) with a 95% positive re-
sult rate and 15 UI/mL for LOD with positive results. Viral load 
determinations were made at the baseline, week 4, at the end 
of antiviral treatment (week 12 or 24) and 12 weeks after an-
tiviral treatment was completed. Transient elastography was 
used for the staging of liver fibrosis (Fibroscan®), stratifying 
patients according stiffness results in fibrosis F0-1 (<7.6 kPa), 
F2 (7.6-9.5 kPa), F3 (9.6- 14.4 kPa) or F4=cirrhosis (>14.4 kPa in 
HCV mono-infected patients and> 14.0 kPa in HIV co-infected 
patients).
grados avanzados de fibrosis disminuyen significativamente la 
efectividad de este tratamiento, lo que motiva la necesidad de 
la adición de ribavirina en pacientes cirróticos. El régimen fue 
seguro y bien tolerado.
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INTRODUCTION
World Health Organization (WHO) states that viral hepati-
tis is a major public health problem and that globally, in 2015, 
71 million people were living with chronic hepatitis C virus 
(HCV) infection [1]. The distribution of HCV by viral genotype 
varies from one region to another, with genotype 3 (G3) being 
the second most prevalent worldwide after genotype 1, which 
implies around 30% of chronic hepatitis C (CHC) cases [2]. In 
addition, G3-HCV chronic infection is characterised by a faster 
progression to liver cirrhosis [3-6] and development of hepato-
cellular carcinoma (HCC) [7], as well as higher rates of hepatic 
steatosis development as the result of multiple mechanisms 
[8-11]. Another remarkable feature of G3-HCV is the lower 
rates of sustained virologic response (SVR) observed with di-
rect-acting antivirals (DAAs), mostly in advanced liver fibro-
sis and/or non-responders to previous treatments, compared 
with other genotypes [12]. Therefore, the evaluation of the 
real-practice effectiveness of antiviral treatment against G3-
HCV chronic infection in the era of DAAs is of special interest.
Treatment of CHC with DAAs in G3-HCV infected patients 
has rapidly evolved in accordance with the efficacy and safe-
ty results of clinical trials were known. Initially, the treatment 
of choice was based on the association of sofosbuvir (SOF) to 
ribavirin (RBV) [13] or peg-interferon (peg-IFN) and RBV, with 
discrete SVR rates; later, the combination of ledipasvir (LDV) 
and SOF, which achieved higher SVR12 rates. Nowadays, the 
American Association for the Study of Liver Diseases (AASLD) 
and the Infectious Diseases Society of America (IDSA) Guid-
ance [14] recommends various therapeutic options based on 
the patient’s previous treatments and the presence/absence of 
cirrhosis, among which is the association of daclatasvir (DCV) 
+ SOF ± RBV [15], with a level of the evidence I that supports 
a strength of recommendation A; this recommendations are 
based on phase III pivotal clinical trials, where this association 
reached a SVR12 of 90% in naïve patients and 86% in treat-
ment-experienced patients, and rates of SVR12 in non-cirrhot-
ic patients of 96% versus 63% in patients with cirrhosis [16]. 
In addition, the analysis of viral response in patients with de-
compensated cirrhosis deserves special attention, due to the 
lower efficacy of antiviral treatment in this subgroup of HCV 
patients, especially in genotype 3 [16, 17], which translates in-
to specific treatment recommendations in the main reference 
guides [14, 18]. However, in real clinical practice, few studies 
have evaluated the use of DCV/SOF ± RBV in G3-HCV infected 
patients, with a limited number of patients with advanced liver 
disease included. Therefore, more data about the use of this 
combination of DAAs will shed more light on clinical outcomes 
in real life.
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servational Post-Authorization Study with Human Medicines” 
by the Spanish Agency of Medicines and Health Products 
(LMF-NAA-2016-01), dependent on the Ministry of Health and 
it was authorized by the Clinical Research Ethics Committee 
(CREC) of the Regional Health Service (number 2016/161). Pa-
tients signed an informed consent approved by the CREC for 
participation in the study and all their data was anonymised. 
RESULTS
Baseline patient demographics and characteristics. A 
total of 950 adult patients started antiviral treatment during 
the study period at our institution, of which 132 were G3-
HCV infected patients. Of these, 14 patients started antiviral 
treatment with different regimens of DCV/SOF ± RBV and 7 
patients who completed the therapeutic regimen did not at-
tend their appointments for the determination of viral load 12 
weeks post-treatment for reasons other than treatment fail-
ure. So, 111 patients constitute the study population for the 
mITT analysis. The average adherence to antiviral treatment 
was 99.3% (98.7% -99.9%, 95%CI). The patients were mostly 
men under 65 years of age, naïve to antiviral treatment, HCV 
mono-infected, with low HCV viral loads (<61 log UI/mL) and 
with advanced fibrosis (58.4% F3-4) although mostly non-cir-
rhotic (table 1). The majority of non-naïve patients had expe-
rienced recurrence to previous antiviral treatment based on 
Peg-Interferon + RBV and only one patient had received pre-
vious DAAs treatment. A small percentage of cirrhotic patients 
had suffered hepatic decompensation before the start of anti-
viral treatment. No patient had, at the beginning of treatment, 
a MELD score (Model of End-stage Liver Disease) higher than 
10 points. Seven patients had a liver transplant. Also, 81.6% of 
cirrhotic patients had a treatment duration of 24 weeks com-
pared to 6.7% of non-cirrhotic patients (p<0.0001). Mean-
while, 81.6% of cirrhotic patients associated RBV with DCV/
SOF versus 13.3% of non-cirrhotic patients (p<0.0001). 
Effectiveness outcomes. All patients achieved virologic 
response at the end of treatment, but 6 of them relapsed af-
ter 12 weeks of follow-up, so the SVR12 was 94.6% (89.9%-
99.3%, 95%CI). One hundred per cent of patients with low fi-
brosis (F0-2) reached SVR12 (92.3%-100%, 95%CI) compared 
to 90.8% (83.0% - 98.6%, 95%CI) of patients with advanced 
fibrosis F3-4 (p=0.03) and the differences in effectiveness be-
tween F3 or F4 patients versus F0-2 patients were very similar 
(p=0.10 or p=0.16, respectively). No statistically significant dif-
ferences were observed in SVR12 among cirrhotic patients with 
or without previous hepatic decompensation (84.6% vs 95.7%, 
p=0.6). SVR12 in naïve and pretreated patients was 96.2% and 
90.3% respectively (p=0.35). One of the 4 patients with Child-
Pugh-Turcotte (CPT) B grade did not reach SVR12 compared 
to 2 of the 32 CPT A grade patients. All patients treated af-
ter liver transplantation reached SVR12, including the patient 
with previous treatment based on DAAs; also, all HIV co-in-
fected patients reached SVR12. SVR12 rates according to ba-
sal fibrosis stage are shown in figure 1. One hundred per cent 
(91.4%-100%, 95%CI) of patients treated with DCV/SOF with 
Adherence rates were made following continuous meas-
urement of the medication acquisition (CMA) method [20], 
during the monthly visits to the Hospital Pharmacy Service 
where the study was conducted, from the beginning to the 
end of the treatment.
The primary efficacy endpoint was the percentage of pa-
tients with SVR12, defined as the ribonucleic acid (RNA) HCV 
un-detectability 12 weeks post-treatment. Secondary efficacy 
variables were based on the analysis of covariates such as the 
presence of cirrhosis, fibrosis stage, previous antiviral treat-
ments, hepatic decompensation, RBV addition to the com-
bination of DAAs, HIV co-infection and liver transplantation. 
Treatment failure was defined as a lack of SVR12 due to a vi-
rologic breakthrough (RNA-HCV detectability in a patient with 
previous RNA-HCV un-detectability on treatment), relapse 
(RNA-HCV detectability 12 weeks post-treatment in a patient 
with RNA-HCV detectability at the end-of-treatment), virolog-
ic failure (no RNA-HCV un-detectability on treatment) or miss-
ing RNA-HCV data 12 weeks post-treatment due to on-treat-
ment withdrawal secondary to severe AEs o death. The primary 
safety endpoint was the percentage of treatment withdrawal 
secondary to severe AEs; secondary variables included the pa-
tient reported AEs stratified into mild, moderate or severe and 
emergent haematological abnormalities stratified according to 
CTCAE v4.0 [21].
Statistical analysis. The Intention-To-Treat (ITT) eval-
uable population included all patients who took at least one 
dose of the prescribed treatment. Both baseline variables (de-
mographics, clinical, histological and laboratory values and 
frequencies) and primary or secondary effectiveness and safe-
ty end-points were collected and analysed by a modified ITT 
(mITT) analysis, including ITT evaluable population patients 
and excluding patients without quantification of RNA-HCV 12 
weeks post-treatment for reasons other than treatment fail-
ure. Quantitative variables were expressed as mean ± stand-
ard deviation (SD) or as median and interquartile range if their 
distributions were normal or non-normal, respectively, and 
were analysed using the Student’s t-test or the Mann-Whit-
ney U-test according to data distribution. Qualitative variables 
were expressed as count and percentage, with confidence in-
terval at 95% and were compared using a Chi-square test or 
Fisher’s exact test. Primary end-points were expressed as a per-
centage and exact 95% binomial confidence interval. To de-
termine any baseline factor influence on primary end-points, 
relative risk with a 95% confidence interval (Katz) for cohort 
studies was calculated using the Chi-square association test 
without Yates correction or Fisher’s exact bilateral test ac-
cording to the number of cases analysed. To detect differences 
between treatment subgroups and predictors of response, a 
univariate analysis was performed. Statistically significant re-
sults were considered when the p value was <0.05. Statistical 
analysis was carried out using the Epidat 3.1 program.
Ethical aspects. This study complies with the Declaration 
of Helsinki of Good Clinical Practices. It was classified as “Ob-
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tion, basal HCV viral load, platelets or albumin levels, 
previous antiviral treatment experience or treatment 
duration (table 2).
Safety outcomes. During follow-up, the rate of 
any degree of AEs secondary to DCV/SOF±RBV was 
57.7% (48.0%-67.3%, 95%CI), although none of the 
patients required treatment withdrawal. Meanwhile, 
4.5% of patients (1.5%-10.2%, 95%CI) developed se-
rious AEs: three patients manifested severe headaches 
(which responded to the use of non-steroidal analge-
sics), one patient reported itching in lower limbs with 
bleeding (associated with grade II thrombocytopenia) 
and one patient presented constipation which re-
quired a visit to the Hospital Emergency Department 
and the use of a rectal enema. Beyond this, 9.9% 
(3.9%-15.9%, 95%CI) of patients developed moderate 
AEs: 5 with fatigue/asthenia, 3 with headache, 2 with 
anxiety and 5 with various symptoms (drowsiness, 
myalgia, insomnia, irritability and diarrhoea). Mild AEs 
were reported by 43.2% of patients (33.6%-52.9%, 
95%CI), presenting a median of 1 event per patient, 
that usually disappeared after the first or second week 
of antiviral treatment. Table 3 shows the main safety 
data. Two patients required hospital admission, one 
secondary to hydropic decompensation and another 
due to respiratory infection. Both were cirrhotic pa-
tients, stage Child-Pugh-Turcotte (CTP) B and finally 
reached SRV12. During the antiviral treatment, no pa-
tient included in this study died.
Neither gender, HIV co-infection, liver transplan-
tation, presence of liver cirrhosis, experience with 
previous antiviral treatments or treatment duration 
statistically had influenced on AEs development (p> 
0.24). However, RBV addition to DCV/SOF had a sig-
nificant negative impact on treatment safety, both at 
the level of general or serious AEs, and, specifically, 
on the development of fatigue/asthenia or pruritus, 
although no patient required treatment withdrawal 
secondary to RBV addition. Also, 16.2% (8.9%-23.5%, 
95%CI) of patients developed different degree cyto-
penias with respect to their baseline pretreatment 
situation: 2 patients experienced severe haematolog-
ical alterations (one grade III neutropenia; other one 
thrombocytopenia grade III) and 11 patients minor 
alterations grade I-II (7 leukopenia, 6 thrombocyto-
penia, 3 anemia and 2 neutropenia). Cytopenia devel-
opment is linked to liver cirrhosis with a relative risk 
of 4.2 (1.7-10.2, 95% CI, p = 0.0016) and to RBV addi-
tion to DCV/SOD, with a relative risk of 5.8 (2.1- 16.9, 95% CI, 
p = 0.0002). Also, 12 patients developed hyperbilirubinemia (8 
grade I and 4 grade II). 
DISCUSSION
Based on the results of our real clinical practice study, DCV/
SOF ± RBV shows a high antiviral effectiveness in G3-HCV in-
RBV reached SVR12, compared to 91.9% (85.0%-98.8%, 95% 
CI) of the patients who did not receive RBV (p=0.083). In the 
cirrhotic patients subgroup, SVR12 was 100% or 40.0% de-
pending on the addition or not of RBV (p=0.001). Other poten-
tial baseline patient or treatment factors that could influence 
treatment effectiveness have not been identified, so no sig-
nificant differences has been seen in SVR12 according to the 
patient’s gender, HIV co-infection, previous liver transplanta-
Characteristic HCV-G3 infected patients (n=111) 
Males, % (n) 78.4% (87)
Age, mean (years ± SD) 50.21±6.98
Age ≥ 65 years, % (n) 1,80% (2)
HIV co-infection, % (n) 24.3% (27)
Fibrosis stage, % (n)
F0-1
F2
F3
F4
9.0% (10)
32.4% (36)
26.2% (29)
32.4% (36)
Elastography kPa, median (rank) 9.95 (4.0–72.1)
Previous clinical decompensation, % (n) 11,7% (13)
CTP classification, % (n)
A
B
88.9% (32)
11.1% (4)
Hepatocellular carcinoma, % (n) 5.4% (6)
Liver transplant, % (n)  6.3% (7)
HCV viral load, log UI/mL (median)
≥ 61 UI/mL, % (n)
6.13
16.2% (18) 
Platelets 109/mL (mean ± SD) 155.5±61.5
Albumin mg/dL (mean ± SD) 4.19±0.37
Bilirubin mg/dL (mean ± SD) 0.77±0.70
Estimated Glomerular Filtration Rate ≥ 60 ml/min, % (n) 92.8% (103)
Previous antiviral treatment, % (n)
Naïve
Treatment-experienced
72.1% (80)
27.9% (31)
Response to previous antiviral treatment, % (n)
Recurrent
Null responder
Intolerant to treatment
Unknown
54.8% (17)
19.4 % (6)
12.9 % (4)
12.9 %(4)
Treatment duration, % (n)
12 weeks
24 weeks
67.6% (75)
32.4% (36)
RBV addition, % (n) 36.9% (41)
Table 1  Baseline patient demographics and 
characteristics.
SD: standard deviation. kPa: kilopascals. HIV: human immunodeficiency virus. CPT: Child-Pugh-
Turcotte. HCV: hepatitis C virus. RVB: ribavirin.
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We have observed a sig-
nificantly lower effectiveness 
of DCV/SOF ± RBV in patients 
with advanced fibrosis F3-4 
compared to patients with 
low fibrosis F0-2 (p = 0.03). 
This is consistent with the re-
sults of the ALLY-3+ clinical 
trial [22], where SVR12 was 
90% in a population of 50 
patients with advanced fibro-
sis or compensated cirrhosis 
and also with the results ob-
served in cirrhotic patients in 
the DCV European Compas-
sionate Use Program (SVR12: 
88-89%) [23], or in the DCV 
French Compassionate Use 
Program (SVR12: 85-90%) 
[24]. Studies in real clini-
cal practice, such as the one 
published by Alonso et al [25] 
documented SVR12 rates of 
94% in G3-HCV cirrhotic pa-
tients (both in CTP A and CTB B/C) and authors suggest that 
this high effectiveness in patients with advanced liver disease 
with regarding previous studies may be due to the fact that 
all cirrhotic patients were treated over 24 weeks with an RBV 
addition to the antiviral regimen. In fact, when analysing the 
influence of RBV on SVR12 in our study, it is observed that 
100% of patients who have been added RBV to DCV/SOF 
reached SVR12 compared to 91.4% in those without RBV, 
and this superior effectiveness is a clinical and statistically 
significant difference when analysed in patients F4 (SVR12: 
100% vs 40%, p = 0.001), confirming the importance of add-
ing RBV to DCV/SOF in cirrhotic G3-HCV infected patients. 
This strategies are still necessary with the most recent DAAs, 
such as elbasvir/grazoprevir, sofosbuvir/velpatasvir (SOF/VEL), 
glecaprevir/pribentasvir (GLE/PRI), that require an RBV addi-
tion and/or antiviral treatment prolongation when the G3-
HCV infected patient is cirrhotic and/or is not naïve to antivi-
ral treatment. Apart from the RBV addition, no other baseline 
factor dependent on the patient or treatment (except for ad-
vanced fibrosis) has been identified as significant on treatment 
effectiveness in this study.
Regarding the analysis in other patient subgroups (al-
though with a limited sample), it is noteworthy that all liver 
transplant patients have achieved SVR12, in accordance with 
the high effectiveness of DCV/ SOF ± RBV observed in patients 
with advanced cirrhosis or post-liver transplantation recur-
rence, in which SVR12 rates of 83% and 91% have been re-
ported respectively [26]. Likewise, treatment has been effective 
in all HIV co-infected patients, reproducing the results of other 
studies in these patients [27-29]. Patients with decompensated 
cirrhosis included in this study obtain an SVR12 around 85%, 
which, while not statistically inferior to the response obtained 
fected patients, with an overall SVR12 rate of 94.6%. This data is 
slightly higher than those observed in the pivotal phase III clini-
cal trial ALLY-3 [16], where the SVR12 overall rate was 89% with 
a study population very similar to our study (25% of cirrhotic 
patients and 34% of previous non-responders to antiviral treat-
ment). These differences in SVR12 are due to the high antiviral 
effectiveness shown in cirrhotic patients in our study compared 
with ALLY-3 (92% vs 66%), because we have implemented ther-
apeutic strategies like 24 weeks treatment duration or RBV addi-
tion in cirrhotic patients (p<0.0001), as the pivotal phase III clin-
ical trial authors postulate to increase the effectiveness of DCV/
SOF. Also, as ALLY-3 clinical trial, our study revealed higher rates 
of SVR12 in naïve compared to experienced patients, although 
this difference is not statistically significant. 
Figure 1 Sustained Virologic Response 12 (95%CI) according to basal fibrosis stage.
Basal factor Relative risk ratio (CI 95%) p
Gender: male vs female 1.07 (1.01 - 1.14) 0.19
HIV co-infection: yes vs no 1.08 (1.01 - 1.14) 0.15
Liver transplantation: yes vs no 1.06 (1.01 - 1.11) 0.99
HCV basal viral load ≥ 61 UI/mL: yes vs no 0.93 (0.78 - 1.10) 0.24
Platelets 109/mL: <100 vs ≥100 0.94 (0.80 - 1.10) 0.31
Albumin (mg/dL): <3.5 vs ≥3.5 0.88 (0.61 - 1.26) 0.32
Treatment-experienced patient: yes vs no 0.94 (0.83 - 1.06) 0.21
Treatment duration: 12 weeks vs 24 weeks 1.05 (0.94 - 1.18) 0.34
Table 2  Evaluation of basal factors associated with 
SVR12.
SVR12: sustained virologic response 12. HIV: human immunodeficiency virus. HCV: 
hepatitis C virus.
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on LDP was around 40% or 60% (depending on the absence or 
presence of RBV) and in regimens with DAC of 61% or 73% re-
spectively; this low effectiveness observed in this study, much 
lower than that achieved in our experience, reinforces the hy-
pothesis of the importance of the addition of RBV to DAAs and 
treatment durations of 24 weeks in HCV genotype 3 patients 
with decompensated cirrhosis, as the authors conclude in their 
work. 
It is also important to assess the results of our study in 
the context of the current reference therapeutic guidelines. 
European Association for the Study of the Liver (EASL) consid-
ers therapeutic options the association of SOF/VEL 12 weeks or 
GLE/PRI 8-12 weeks (according to previous therapeutic expe-
rience) for patients HCV genotype 3 without cirrhosis, GLE/PRI 
12-16 weeks (according to previous therapeutic experience) or 
SOF/VEL/voxilaprevir (SOF/VEL/VOX) for 12 weeks for patients 
with compensated cirrhosis, and SOF/VEL + RBV 12 weeks or 
SOF/VEL 24 weeks (if intolerance or contraindication to RBV) 
in patients with compensated cirrhosis (around 96%), could be 
considered clinically relevant in the current context of elevat-
ed effectiveness of antiviral treatment. Some previous studies 
have analysed the efficacy and safety of DAAs in HCV patients 
with decompensated cirrhosis. Curry MP et al [30] conducted 
an open phase 3 clinical trial (ASTRAL 4) that evaluated SOF 
associated with velpatasvir with or without RBV for 12 weeks 
or without RBV for 24 weeks in HCV patients genotype 1 to 6 
with decompensated cirrhosis; RVS12 in the small group of 39 
HCV genotype 3 patients was 50% if RBV had not been asso-
ciated with DAAs and 85% in those who did associate it; these 
results are very similar to those of our study and reinforce 
the importance of the RBV addition to the antiviral regimen 
in patients with decompensated cirrhosis. Also, Foster GR et 
al [31] evaluated the response to a 12-week treatment with 
SOF+DAC or SOF/LPV associated or not with RBV (according to 
non-protocolized medical criteria) in 192 HCV genotype 3 pa-
tients with decompensated cirrhosis; SVR12 in regimens based 
Event (%) GLOBAL
(n=111)
DCV/SOF
(n=70)
DCV/SOF+RBV
(n=41)
p
Treatment withdrawal due to drug-related AE 0.0% 0.0% 0.0% 0.999
Any drug-related AE 57.7% 45.7% 75.6% 0.004
Any drug-related serious AE 7.2% 1.4% 17.1% 0.007
Hospitalization during treatment 1.8% 0.0% 4.9% 0.260
Death 0.0% 0.0% 0.0% 0.999
Any grade AE with global incidence > 2.5%:
Fatigue/asthenia
Headache
Insomnia
Gastrointestinal upset
Nausea
Anxiety
Diarrhoea
Myalgia
Irritability
Constipation
Pruritus
36.0% 
21.6%
9.0% 
7.2%
5.4%
4.5%
4.5%
3.6%
3.6%
3.6%
3.6%
25.7%
18.6%
5.7%
5.7%
5.7%
4.3%
4.3%
1.4%
1.4%
2.9%
0.0%
53.7%
26.8%
14.6%
9.8%
4.9%
4.9%
4.9%
7.3%
7.3%
4.9%
9.8%
0.006
0.435
0.215
0.678
0.805
0.742
0.742
0.281
0.281
0.981
0.033
Emergent haematological abnormalities
Leukopenia
Thrombocytopenia
Anaemia
Neutropenia
All
6.3%
5.4%
2.7%
2.7%
17.1%
0.0%
2.9%
0.0%
2.9%
5.8%
17.1%
14.6%
7.3%
7.3%
46.3%
0.0007
0.0498
0.0481
0.3565
<0.001
Table 3  Percentage of patients with drug-related 
adverse events
DCV: daclatasvir. SOF: sofosbuvir. RBV: ribavirin. AE: adverse event.
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